{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"5.0","upperLimit":"21.7","value":"13.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"-Progression per IMWG Criteria","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Level 0: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (27 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 1: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (36 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 2: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (45 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 3: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (56 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.","id":"OG000","title":"Phase I - Part 1"},{"description":"Phase I Part 2 Cohort 0: Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.\n\nPhase 2: Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"OG001","title":"Phase 2 (Includes Phase I - Part 2 Participants)"}],"paramType":"MEDIAN","populationDescription":"This outcome measure is for Phase 2 (including Phase I Part 2) participants only. Phase I Part 2 and Phase 2 participants who began alternative anti-multiple myeloma treatment prior to progression were censored.","reportingStatus":"POSTED","timeFrame":"Through completion of follow-up (median follow-up was 23.3 months)","title":"Progression-free Survival Time (Phase 2 Only)","type":"SECONDARY","unitOfMeasure":"months"}